Ajinomoto Bio-Pharma Services and XL-protein GmbH, a German biopharmaceutical company, have entered a Strategic Alliance, under which Ajinomoto will apply its Corynex expression system together with XL-protein’s PASylation technology for plasma half-life extension to develop a series of therapeutic compounds. Financial terms were not disclosed.   The companies have established the efficient production of a PASylated proprietary GLP-1 variant with extended half-life at lab scale yielding ...